Technical Analysis for LCTX - Lineage Cell Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 0.91 -1.09% -0.01
LCTX closed down 1.09 percent on Friday, August 7, 2020, on 60 percent of normal volume. It was able to find support at its 50 day moving average. It was able to bounce off of its 200 day moving average, an important long-term support line.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical LCTX trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
50 DMA Support Bullish 0.00%
Upper Bollinger Band Walk Strength 0.00%
Earnings Movers Other 0.00%
Outside Day Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 200 DMA Bullish -1.09%
Crossed Above 50 DMA Bullish -1.09%
MACD Bullish Centerline Cross Bullish -1.09%
Pocket Pivot Bullish Swing Setup -1.09%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Biotechnology Life Sciences Biology Immunotherapy Stem Cells Non Small Cell Lung Cancer Osteoarthritis Drug Delivery Cell Therapy Injuries Degenerative Diseases Stem Cell Therapy Human Disease Biotime Dry Age Related Macular Degeneration

Is LCTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.67
52 Week Low 0.5339
Average Volume 1,315,708
200-Day Moving Average 0.89
50-Day Moving Average 0.89
20-Day Moving Average 0.83
10-Day Moving Average 0.86
Average True Range 0.06
ADX 13.83
+DI 25.36
-DI 17.28
Chandelier Exit (Long, 3 ATRs ) 0.80
Chandelier Exit (Short, 3 ATRs ) 0.90
Upper Bollinger Band 0.92
Lower Bollinger Band 0.74
Percent B (%b) 0.93
BandWidth 21.34
MACD Line 0.01
MACD Signal Line -0.01
MACD Histogram 0.0136
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.08
Resistance 3 (R3) 1.08 1.02 1.05
Resistance 2 (R2) 1.02 0.98 1.02 1.04
Resistance 1 (R1) 0.97 0.96 0.94 0.97 1.03
Pivot Point 0.91 0.91 0.90 0.91 0.91
Support 1 (S1) 0.86 0.87 0.83 0.86 0.79
Support 2 (S2) 0.80 0.85 0.80 0.78
Support 3 (S3) 0.75 0.80 0.77
Support 4 (S4) 0.75